Clinical Updates in HR+ HER2- eBC

W

AACR 2022 Multiomic, Plasma-Only ctDNA Assay Identifies Breast Cancer Patients With MRD and Predicts Distant Recurrence

By Wolfgang Janni 6 Videos
168 views
April 15, 2022
Comments 0
Login to view comments. Click here to Login
51:11

2022 Nebraska Oncology Society SABCS Review: Updates in the Manageme…

Nebraska Oncology Society

T. Mamounas

696 views
40:21

2022 Nebraska Oncology Society SABCS Review: Neo(Adjuvant) Breast Ca…

Nebraska Oncology Society

L. Kennedy

229 views
33:55

Improving Outcomes for Patients With HR+ BC: From Metastatic to Earl…

Keck School of Medicine of USC

H. Rugo

381 views
32:59

I SPY 2.2: Responsive, Adaptive Trial to Prioritize Promising Invest…

Keck School of Medicine of USC

L. Esserman

624 views
08:19

SABCS 2021 Interim Analysis of the PREDICT Registry: Changes in Trea…

SABCS 2021 Conference Coverage on VuMedi

P. Whitworth

272 views
11:02

Genomic Assays in Early Stage HR+ Breast Cancer

Kevin Kalinsky

863 views
50:02

2022 Moffitt Cancer Center Updates in Breast Cancer Immunotherapy

Moffitt Cancer Center

H. Khong

253 views
24:14

2022 Nebraska Oncology Society SABCS Review: Updates in Radiation On…

Nebraska Oncology Society

W. Woodward

89 views
25:40

2022 Cleveland Clinic Updates on the Management of HR+ Breast Cancer

Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia

M. Kruse

203 views
10:45

Tailoring Breast Cancer Radiation Therapy in the 21st Century

ecancer

P. Poortmans

202 views
16:56

The RxPONDER Trial and Its Impact on Best Clinical Practice in HR+/H…

ecancer

C. Markopoulos, G. Curigliano

241 views
12:48

Adjuvant Capecitabine for EBC: 15-Year OS Results of the FinXX Trial

Heikki Joensuu

134 views